Sm08502-onc-01

Author: jdze

August undefined, 2024

WebbThis study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available. …

Effects of SM08502, a novel, oral small-molecule inhibitor of Wnt ...

Webb[VIRTUAL] SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate … Webb13 dec. 2024 · SM08502 inhibited cell viability in all 14 cell lines (regardless of KRAS status) (EC 50 =0.072-0.526 μM). In Capan-1, HPAFII, and Panc1 cells, 1 μM SM08502 … ear pain when lying on pillow

A Study Evaluating the Safety and Pharmacokinetics of

Webb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology … Webb[VIRTUAL] SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt and cyclin D-CDK4/6-RB pathway inhibition in hormone-receptor-positive (HR+) breast cancer models (AACR-II 2024) Webb17 nov. 2024 · Drug: SM08502 Study Type Interventional Enrollment (Actual) 82 Phase Phase 1 Contacts and Locations This section provides the contact details for those … ear pain when lying down

68 Ga-PSMA scans available in USA? - Advanced Prostate.

EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE …

Webb28 nov. 2024 · A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors The safety and scientific validity of … WebbSAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CL ct4 hudWebbOmipalisib C25H17F2N5O3S CID 25167777 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ... ear pain when pressing back of ear

"WebbThe study will evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor efficacy of SM08502 administered orally, once daily, following a 28-day treatment cycle (Part 1A). … " - Sm08502-onc-01

Sm08502-onc-01

Clinical Trial: NCT03355066 - My Cancer Genome

Webb6 jan. 2024 · SM08502 inhibited the Wnt signaling pathway, both in vitro and in vivo, in colorectal cancer models. Inhibition of CLK2 and CLK3 affected alternative splicing, which underlies inhibition of aberrant Wnt signaling. SM08502 also demonstrated significant anti-tumor effects in xenograft models of gastrointestinal cancer. Webb31 mars 2024 · SM08502 is a first-in-class CLK inhibitor being investigated in a Phase 1 clinical trial for subjects with advanced solid tumors (NCT03355066). Keywords: …

Did you know?

Webb16 dec. 2024 · Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and … http://www.usalifesciences.com/us/portal/news_details.php?news_id=28606851k$SnKVXke2weSNs

Webb29 sep. 2024 · add_box. SAN DIEGO, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering … WebbSM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer …

Webb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC … WebbSM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects as Monotherapy and in …

Webb31 mars 2024 · In an iterative screening campaign of >1500 compounds, SM08502 was developed as a small-molecule CLK inhibitor with IC 50 values of 0.002 μM for CLK2 and …

Webb20 okt. 2024 · Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC. Subjects will receive increasing doses of SM08502 with fixed doses of … ear pain when sickWebbA Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid … ct4 hpWebbCANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment Salubris Biotherapeutics Announces … ct4 blackwing mpgWebbCirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research [1] . Cirtuvivint (SM08502) inhibits … ct4k notesWebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and … ear pain when touching earWebbSM08502-ONC-01: A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with … ear pain when yawning and belchingWebb(C) SM08502 is more potent than PRI-724 in an SW480 Wnt reporter (TOPflash) assay. Cells were treated with a 3-fold 10-point titration of doses of SM08502 or PRI-724 … ear pain when tilting head